SCHEMBL13615656

SCHEMBL13615656

Cc1ccc(N(c2ccc(C(C)(C)C)cc2)c2ccc3c(-c4ccc(N(c5ccccc5)c5ccccc5)cc4)c4cc(N(c5ccc(C)cc5)c5ccc(C(C)(C)C)cc5)ccc4c(-c4ccc(N(c5ccccc5)c5ccccc5)cc4)c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
CYP2D6 P10635 2/20 0.33
GPR84 Q9NQS5 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
RAB9A P51151 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 3/20 0.32
MAPT P10636 3/20 0.32
HCRTR2 O43614 1/20 0.32
ACHE P22303 2/20 0.32
AR P10275 1/20 0.32
HPGD P15428 1/20 0.32
TNKS O95271 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615646 0.94 TP53 (0.37) TP53SMN1; SMN2PTGESALOX5CYP2D6
SCHEMBL12928329 0.94 TP53 (0.37) TP53SMN1; SMN2PTGESALOX5CYP2D6
SCHEMBL13615686 0.94 TP53 (0.37) TP53SMN1; SMN2PTGESALOX5CYP2D6
SCHEMBL13615713 0.93 NPSR1 (0.36) TSHRTP53SMN1; SMN2PTGESALOX5
SCHEMBL12770708 0.92 PTGES (0.41) TP53SMN1; SMN2PTGESALOX5CYP2D6
SCHEMBL10304794 0.92 PTGES (0.37) TP53SMN1; SMN2PTGESALOX5CYP2D6
SCHEMBL10304792 0.90 PTGES (0.38) TP53SMN1; SMN2PTGESALOX5CYP2D6
SCHEMBL14099861 0.90 ACHE (0.37) TSHRSMN1; SMN2CYP2D6NPSR1RAB9A
SCHEMBL15762783 0.90 ACHE (0.37) TSHRSMN1; SMN2CYP2D6NPSR1RAB9A
SCHEMBL13615643 0.90 ACHE (0.37) TSHRSMN1; SMN2CYP2D6NPSR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed
EP-2103666-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090273277-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, ORMDL3, CHRM2 TSHR 3938/4885TP53 2524/4885SMN1; SMN2 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.